Bronchodilators Market by Drug class (Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor and Combination Drugs), by Indication (Asthma, COPD, and Others), and Route of Administration (Oral, Injection, and Inhaler): Global Opportunity Analysis and Industry Forecast, 2019–2026
- ALL3815949
- 207 Pages
- February 2020
- Medical Devices
Surge in prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD) across the globe is the major factor driving the bronchodilators market growth. Other factors such as rise in incidence of respiratory diseases due to cigarette smoking also boost the market growth. In addition, rise in disposable income, geriatric population, and increase in awareness for healthcare among people are anticipated to boost the market growth. However, side effects associated with bronchodilators and government regulations related to the safety & efficacy of these drugs are anticipated to hamper the market growth. Furthermore, ongoing R&D activities related to bronchodilators are anticipated to present new opportunities for the market.
The market is segmented on the basis of indication, drug type, route of administration, and region. On the basis of indication, it is categorized into asthma, chronic obstructive pulmonary disease (COPD), and others. By drug type, it is classified into sympathomimetics, anticholinergics, phosphodiesterase inhibitors, and combination drugs. On the basis of route of administration, it is categorized into oral, injection, and inhaler. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vectura Group plc., and Abbott Laboratories are provided in this report.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Indication
• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Others
By Drug Type
• Sympathomimetics
• Anticholinergics
• Phosphodiesterase Inhibitor
• Combination Drugs
By Route of Administration
• Oral
• Injection
• Inhaler
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Boehringer Ingelheim
• GlaxoSmithKline
• F. Hoffmann-La Roche AG
• AstraZeneca plc
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Vectura Group plc.
• Abbott Laboratories
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of buyers
3.3.2. Low bargaining power of suppliers
3.3.3. Moderate threat of substitutes
3.3.4. Low threat of new entrants
3.3.5. Moderate competitive rivalry
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in incidence of asthma and COPD
3.5.1.2. Surge in government initiatives
3.5.2. Restraint
3.5.2.1. Side effects associated with bronchodilators
3.5.3. Opportunity
3.5.3.1. Various growth opportunities in emerging economies
CHAPTER 4: BRONCHODILATORS MARKET, BY INDICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Asthma
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market share analysis, by country
4.3. Chronic obstructive pulmonary disease (COPD)
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast
4.3.3. Market share analysis, by country
4.4. Others
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market share analysis, by country
CHAPTER 5: BRONCHODILATORS MARKET, BY DRUG TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Sympathomimetics
5.2.1. Market size and forecast
5.2.2. Market share analysis, by country
5.3. Anticholinergics
5.3.1. Market size and forecast
5.3.2. Market share analysis, by country
5.4. Phosphodiesterase Inhibitors
5.4.1. Market size and forecast
5.4.2. Market share analysis, by country
5.5. Combination Drugs
5.5.1. Market size and forecast
5.5.2. Market share analysis, by country
CHAPTER 6: BRONCHODILATORS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Oral
6.2.1. Market size and forecast
6.2.2. Market share analysis, by country
6.3. Injection
6.3.1. Market size and forecast
6.3.2. Market share analysis, by country
6.4. Inhalers
6.4.1. Market size and forecast
6.4.2. Market share analysis, by country
CHAPTER 7: BRONCHODILATORS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by country
7.2.3. Market size and forecast, by indication
7.2.4. Market size and forecast, by drug type
7.2.5. Market size and forecast, by route of administration
7.2.5.1. U.S. market size and forecast, by indication
7.2.5.2. U.S. market size and forecast, by drug type
7.2.5.3. U.S. market size and forecast, by route of administration
7.2.5.4. Canada market size and forecast, by indication
7.2.5.5. Canada market size and forecast, by drug type
7.2.5.6. Canada market size and forecast, by route of administration
7.2.5.7. Mexico market size and forecast, by indication
7.2.5.8. Mexico market size and forecast, by drug type
7.2.5.9. Mexico market size and forecast, by route of administration
7.3. Europe
7.3.1. Key growth factors and opportunities
7.3.2. Europe Market size and forecast, by country
7.3.3. Europe Market size and forecast, by indication
7.3.4. Europe Market size and forecast, by drug type
7.3.5. Europe Market size and forecast, by route of administration
7.3.5.1. Germany market size and forecast, by indication
7.3.5.2. Germany market size and forecast, by drug type
7.3.5.3. Germany market size and forecast, by route of administration
7.3.5.4. France market size and forecast, by indication
7.3.5.5. France market size and forecast, by drug type
7.3.5.6. France market size and forecast, by route of administration
7.3.5.7. UK market size and forecast, by indication
7.3.5.8. UK market size and forecast, by drug type
7.3.5.9. UK market size and forecast, by route of administration
7.3.5.10. Rest of Europe market size and forecast, by indication
7.3.5.11. Rest of Europe market size and forecast, by drug type
7.3.5.12. Rest of Europe market size and forecast, by route of administration
7.4. Asia-Pacific
7.4.1. Key growth factors and opportunities.
7.4.2. Asia-Pacific market size and forecast, by country
7.4.3. Asia-Pacific market size and forecast, by indication
7.4.4. Asia-Pacific market size and forecast, by drug type
7.4.5. Asia-Pacific market size and forecast, by route of administration
7.4.6.1. Japan market size and forecast, by indication
7.4.6.2. Japan market size and forecast, by drug type
7.4.6.3. Japan market size and forecast, by route of administration
7.4.6.4. China market size and forecast, by indication
7.4.6.5. China market size and forecast, by drug type
7.4.6.6. China market size and forecast, by route of administration
7.4.6.7. India market size and forecast, by indication
7.4.6.8. India market size and forecast, by drug type
7.4.6.9. India market size and forecast, by route of administration
7.4.6.11. Rest of Asia-Pacific market size and forecast by indication
7.4.6.12. Rest of Asia-Pacific market size and forecast, by drug type
7.4.6.13. Rest of Asia-Pacific market size and forecast, by route of administration
7.5. LAMEA
7.5.1. Key growth factors and opportunities
7.5.2. Market size and forecast, by country
7.5.3. LAMEA market size and forecast, by indication
7.5.4. LAMEA market size and forecast, by drug type
7.5.5. LAMEA market size and forecast, by route of administration
7.5.5.1. Brazil market size and forecast, by indication
7.5.5.2. Brazil market size and forecast, by drug type
7.5.5.3. Brazil market size and forecast, by route of administration
7.5.5.4. Saudi Arabia market size and forecast, by indication
7.5.5.5. Saudi Arabia market size and forecast, by drug type
7.5.5.6. Saudi Arabia market size and forecast, by route of administration
7.5.5.7. South Africa market size and forecast, by indication
7.5.5.8. South Africa market size and forecast, by drug type
7.5.5.9. South Africa market size and forecast, by route of administration
7.5.5.10. Rest of LAMEA market size and forecast, by indication
7.5.5.11. Rest of LAMEA market size and forecast, by drug type
7.5.5.12. Rest of LAMEA market size and forecast, by route of administration
CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. AstraZeneca plc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Boehringer Ingelheim International GmbH
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. GlaxoSmithKline Plc.
8.4.1. Company overview
8.4.2. Operating business segments
8.4.3. Product portfolio
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. F. Hoffmann-La Roche Ltd.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.6. Novartis AG.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Pfizer Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. SANOFI
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Teva Pharmaceutical Industries Ltd.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. Vectura Group Plc.
8.10.1. Company overview
8.10.2. Operating business segments
8.10.3. Product portfolio
8.10.4. Business performance
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
